Incretin Agonists And CPAP In Adults With Diabetes, Obesity, OSA

Incretin agonists, including the GLP-1 receptor agonists and the dual incretin tirzepatide, are redefining our understanding of obstructive sleep apnea (OSA) in obese patients with T2D. While weight loss can reduce severity of OSA and alleviate sleep-related symptoms but does not cure OSA, the magnitude of weight loss achieved with some of these medications is often considered in treatment decisions. The gold standard for treatment of OSA remains continuous positive airway pressure (CPAP), which is effective in keeping the airway open at night. The major challenge is how to safely and efficiently combine these two treatments in the management of obese individuals with T2D.

Why It Matters

Obstructive sleep apnea (OSA) creates a triad of increased risk for a variety of severe cardiometabolic disorders including obesity and type 2 diabetes. During sleep, the airway collapses within the upper airway, repeatedly disrupting breathing. The decrease in oxygen can force a person to wake up at irregular times throughout the night leading to poor sleep quality. OSA can cause symptoms such as loud snoring, excessive daytime sleepiness, wakening up with a headache and poor sleep quality. Should you have OSA, your blood pressure can remain elevated throughout the day placing you at risk for increased risk for heart disease. Road safety and job performance can also be compromised by the symptoms of OSA. Importantly, for individuals with diabetes, OSA can have a particularly negative effect on blood sugar levels, potentially even affecting the dose of medication required to control blood sugar levels.

For individuals who suffer from moderate to severe obstructive sleep apnea (OSA), Continuous Positive Airway Pressure (CPAP) is the established treatment. CPAP is simple to use and immediately begins working as soon as it is turned on. By delivering constant and controlled levels of air pressure through a mask and tubing connected to a blower, the airway is kept open, thereby preventing the collapse of the airway that occurs with apnea and hypopnea. The benefits of treating sleep apnea with effective CPAP use include greater energy and enhanced quality of life, and have even been shown to lower high blood pressure. However, there are many patients for whom adherence to CPAP can be a problem. Individuals with moderate to severe sleep apnea require CPAP to treat their condition, but they often also experience a host of challenges that can keep them from using the device nightly, including CPAP-related discomfort, CPAP mask leaks, claustrophobia, nasal congestion, and the social image concern of what others will think if they use a mask at night. In addition, there are a number of other system limitations that are placed on health management of sleep disorders, such as availability of equipment (e.g. monitoring devices) and wait times between scheduling a sleep study and a follow-up appointment.

Weight loss is known to improve OSA, but achieving long-term, clinically significant weight loss can be a problem of great magnitude. Body fat, particularly central fat around the neck and trunk, impairs airway function by increasing collapsibility and reducing functional lung volume, thereby predisposing to sleep obstruction. Diet and physical activity have been demonstrated to alleviate OSA symptoms in some individuals, but such beneficial lifestyle changes are hard to sustain in many individuals, notably individuals with diabetes, those with limited time or financial resources, and individuals with food insecurity and/or depression. For a select group of patients, very effective OSA-reducing weight loss can be achieved through bariatric surgery; however, many find this option nonacceptable or nonfeasible.

Incretin agonists offer an “obesity third way” between lifestyle and surgical obesity interventions: moderate weight loss and simultaneous improvements in major metabolic parameters. Glucagon-like-protein-1 (GLP-1) receptor agonists and dual incretin therapies (DITPs) reduce hunger and increase feelings of fullness/satiety and have been demonstrated to promote clinically significant weight loss among a subset of type 2 diabetes patients. In addition to weight loss, these agents also offer improvement in glycemic control, and often a reduction in the need for other diabetes medications. In addition, patients with weight induced OSA may require less CPAP pressure, a different mask, or even an objective trial off of CPAP following repeated evaluation as weight loss occurs.

The pharmacologic treatment for obesity associated with OSA has reached a new milestone with the recent approval of tirzepatide for the treatment of obesity in adults with moderate to severe Obesity-Related OSH (OROSH). High-quality evidence now exists from the randomised trials that weight loss can be part of the treatment approach for some individuals with OSA. The results are highly variable with remission not achieved in the majority of patients and it is inappropriate to inform patients that they will no longer require CPAP with a simple weekly injection. For individuals with severe OSHA, the immediate protective effects of CPAP still remain.

Decisions about health care choices have public health implications, namely effects on the health budgets and access to care. The choices also have health equity implications. For individuals with OSA who are obese, CPAP is effective and has few adverse effects, making it optimal therapy. However, it is costly because it requires a device, a large supply of masks, tubes, and batteries, and someone to trouble shoot problems and do follow-up CPAP setups. In contrast, the incretin-based medications for weight loss are expensive, and patients who choose them for weight loss may require prolonged treatment to maintain weight loss. Payers’ decisions about whether to cover these medications broadly could decrease demand for effective device therapy for OSA, thereby decreasing demand for costly devices and for the costly titration studies required for prescription. However, when these medications are discontinued, patients return to their prem treatment weights and experience the same sequelae of severe OSA. Future health system models should consider that remote health delivery is not intended to replace all in-person direct clinical contact and the future health system model should be a hybrid of models that ensure optimal clinical outcomes for individual patients.

Who It Affects

The patient most directly impacted by a therapy for treating sleep would be the adult with type 2 diabetes and obesity who also has OSA. Many of these individuals have other comorbid conditions like hypertension, dyslipidemia, fatty liver disease, and heart disease. They are on multiple prescribable therapies, often difficult to manage and could benefit from a therapy that treats weight and glycemia improving overall cardiometabolic risk. Perhaps even improving sleep-­disordered breathing.

For those patients who have challenges with CPAP adherence, incorporating incretin therapy into the treatment armamentarium may provide an alternative avenue to initiating treatment for OSA that is more palatable to the patient. Once sleep related symptoms subside, the patient can then be targeted with oral devices or weight loss strategies aimed at reducing excessive daytime sleepiness. Many of these patients cannot tolerate initial use of CPAP or use it intermittently. It is also important to recognize that reduced symptoms do not equate with resolution of OSA. Hence, patients who stop CPAP must have a plan in place prior to discontinuing use of CPAP to re-test with an objective measure of sleep.

Future shifts in sleep disorder care will require sleep professionals, respiratory therapists, and DME services to take patients down a different path of care. As the trend of incretin therapy increases, sleep teams will be asked if patients on CPAP can safely decrease their pressure, if patients would be better off on an auto adjust CPAP, or if patients should defer CPAP treatment until they have lost weight. Each program will need to develop a plan for repeating sleep studies, weeding through patient reported symptoms, and quickly adapting to changes in their patient’s CPAP needs as they continue to lose weight.

Primary care and endocrinology professionals will take on an increased role in screening for OSA symptoms and managing patients on incretin therapies. The majority of prescriptions for these medications will originate outside of sleep clinics, and therefore physicians and nurse practitioners managing patients with diabetes and obesity will need effective tools to screen patients for symptoms of snoring, reported apneas at night, daytime sleepiness, resistant hypertension and poor sleep quality. Additionally, practitioners need effective pathways for referral to home sleep testing and polysomnography as well as mechanisms to communicate information such as CPAP compliance, weight and diabetes medications with the sleep specialist.

Payers and policymakers will play a significant role in the widespread adoption of effective obesity treatment containing both obesity therapy and OSA therapy for patients with obesity. Coverage policies for incretin therapies such as Victoza, Nexavar, Byetta and others including prior authorization and duration of therapy may need to be revised to ensure that patients receive adequate time on these medications to achieve weight loss and concomitant resolution of OSA symptoms. Additionally, coverage and reimbursement for CPAP supplies, mask refits, and home telemonitoring could be crucial in ensuring adherence to CPAP therapy. Currently, a payer may cover effective obesity therapy, but not effective OSA therapy, resulting in suboptimal treatment of the obese patient. Alternatively, coordinated reimbursement strategies can ensure that patients receive effective therapy for both obesity and OSA.

To address the public health implications of OSA, new treatments are under investigation, including medications that work through the gut hormone system (the incretin pathway). As these potential treatments move forward in clinical trials, it is likely that they will remain out of reach for many patients due to cost. Alternatively, primary care physicians could potentially offer an oral version of these medications to patients with OSA, but the treatments then remain out of reach for vulnerable populations due to lack of access to medical care. Thus, it is crucial to consider how to ensure that these new treatments do not increase health access disparities, and instead promote better health outcomes for all populations, particularly vulnerable populations who already experience disparities in access to health care for a variety of reasons. Low income and rural populations experience barriers to accessing medical care for a variety of reasons. In addition, some racial/ethnic groups experience greater burdens of obesity, diabetes and OSA and have been shown to delay receiving sleep testing and have difficulty accessing equipment and subsequent treatment, such as CPAP.

What Changes

• Clinical practice is likely to shift toward combined care models that coordinate metabolic treatment with sleep therapy rather than treating OSA as a stand-alone device problem. A practical approach is to optimize CPAP for immediate symptom control and airway protection while initiating incretin therapy when appropriate for diabetes and obesity. As weight changes, sleep teams can reassess CPAP settings and determine whether a repeat sleep study is needed. This requires clear communication between primary care, endocrinology, and sleep medicine.
• A stepwise pathway can help clinicians decide when and how to adjust CPAP during weight loss. First, confirm baseline severity with objective testing and document symptoms, blood pressure, and cardiometabolic status. Second, initiate or optimize CPAP with strong adherence support, including mask fitting, humidification, and troubleshooting in the first weeks. Third, if weight loss is substantial and sustained, reassess symptoms and review device data for residual events and leak. Fourth, consider repeat sleep testing before any major change in treatment, especially before discontinuing CPAP. This protects patients from false reassurance and prevents avoidable recurrence.
• For some patients, incretin-driven weight loss may reduce OSA severity enough to change CPAP needs, but medication does not replace CPAP for everyone. Some will require lower pressures and may tolerate CPAP better once nasal congestion improves and masks fit differently after weight loss. Others may still have anatomical drivers of OSA, such as craniofacial structure or airway collapse patterns, and they may need CPAP long term even with significant weight reduction. Clinicians should communicate that the goal is improved health and sleep, not simply device avoidance.
• Clinical decisions should remain patient-centered and start with clear goals. Some patients prioritize improved daytime alertness and fewer cardiovascular risks. Others prioritize fewer medications or a lower burden of equipment. Clinicians should ask whether the patient’s main goals are glycemic control, weight loss, reduced sleepiness, blood pressure improvement, or a supervised attempt to reduce CPAP dependence. Goals guide which outcomes to track and how often to reassess.
• Shared decision-making must include side effects, contraindications, and practical barriers. Incretin agonists commonly cause gastrointestinal side effects, especially during dose escalation, and may not be appropriate for everyone. Patients should also understand that benefits may depend on continued use and that weight regain can occur after stopping therapy, which may lead to recurrence of OSA. For CPAP, patients should be counseled that adherence drives benefit and that troubleshooting is part of the process, not a sign of failure.
• Health systems and insurers will face trade-offs between medication coverage and device-based care, and cost-effectiveness will not be uniform across patients. Short-term reductions in CPAP supply use may not offset long-term medication spending if drugs must be continued indefinitely. On the other hand, if medication improves weight, glucose, blood pressure, and inflammation, there may be downstream savings from fewer complications. Payment models that reward coordinated outcomes, rather than siloed spending, may be better suited to this combined care era.
• Workforce and access needs will change as more clinicians prescribe obesity pharmacotherapy and more sleep programs monitor patients whose OSA severity may shift. Training needs include safe incretin prescribing, management of side effects, pregnancy counseling when relevant, and coordination with sleep testing and CPAP follow-up. Sleep programs will need clear protocols for re-testing after weight loss and for managing patient requests to stop CPAP.
• Equity should be planned from the start, not added later. Practical steps include expanding access to home sleep testing, supporting telehealth follow-up for CPAP adherence and medication monitoring, and designing prior authorization pathways that do not exclude patients who have the greatest need but the least ability to navigate paperwork. Health systems can also prioritize multidisciplinary clinics that serve high-risk populations, pairing obesity treatment with sleep evaluation and behavioral coaching.
• Looking ahead, the best outcomes will likely come from integrated care that combines CPAP for immediate airway control with incretin therapy for sustained weight and metabolic improvement. Medication can be a powerful tool for patients whose OSA is strongly driven by excess weight, but CPAP remains the most reliable method for preventing airway collapse during sleep, especially in severe disease. A balanced, evidence-informed pathway helps the right patients receive the right mix of therapies at the right time.

References:

https://pmc.ncbi.nlm.nih.gov/articles/PMC12723546/ https://pmc.ncbi.nlm.nih.gov/articles/PMC11009690/